Search company, investor...
Search

Predict your next investment

Merck & Co. company logo
Corporation
HEALTHCARE | Drug Development
merck.com

See what CB Insights has to offer

Investments

24

Portfolio Exits

26

Partners & Customers

10

Service Providers

2

About Merck & Co.

Merck & Co. (NYSE: MRK) is a global healthcare company that specializes in prescription medicines, vaccines, biologic therapies, and animal health products. It provides a wide range of products such as Antivenin, Bridion, Crixivan, Delstrigo, Follistim and more. The company was founded in 1891 and is based in Kenilworth, New Jersey.

Merck & Co. Headquarters Location

2000 Galloping Hill Road

Kenilworth, New Jersey, 07033,

United States

908-740-4000

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Merck & Co.

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Merck & Co. in 2 Expert Collections, including Synthetic Biology.

S

Synthetic Biology

382 items

F

Fortune 500 Investor list

590 items

This is a collection of investors named in the 2019 Fortune 500 list of companies. All CB Insights profiles for active investment arms of a Fortune 500 company are included.

Merck & Co. Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Merck & Co. Rank

Latest Merck & Co. News

Insights on the Downstream Processing Global Market to 2030 - Players Include 3M, Danaher, Thermo Fisher Scientific and Merck & Co Among Others

Sep 30, 2022

According to this report the Downstream Processing Market Size at $21.8 billion in 2020, and is estimated to reach $92.0 billion by 2030, growing at a CAGR of 13.5% from 2021 to 2030. Downstream processing refers to the recovery and purification of biosynthetic products, particularly pharmaceuticals, from natural sources such as animal or plant tissue or fermentation broth. It is an essential step in the manufacture of pharmaceuticals such as antibiotics, hormones (e.g., insulin and human growth hormone), antibodies (e.g., infliximab and abciximab) and vaccines; antibodies and enzymes used in diagnostics; industrial enzymes; and natural fragrance and flavor compounds. Downstream processing is usually considered a specialized field in biochemical engineering. The key factors that drive the growth of the market are increase in demand for biopharmaceuticals as downstream processing plays a key role in providing pure biopharmaceutical products. In addition, rise in R&D expenditure for biopharmaceutical products majorly drive the growth of the market. Furthermore, rise in adoption of single-use systems, low risk of product cross contamination and cost-effectiveness are the key factors anticipating the growth of market in upcoming years. In addition, single-use system in downstream processing is highly efficient and cost-effective, which attract pharmaceutical manufacturers to adopt disposable bioprocessing products drive the growth of the market in upcoming years. However, dearth and shortage of skilled bioprocess engineers is expected to restrain the market growth in upcoming years. Moreover, untapped markets such as China and India, offer profitable opportunities to expand this market. The downstream processing market is segmented on the basis of technique, product, system application, end user, and region. By technique, it is categorized into purification, separation, and clarification/concentration. Depending on product, it is classified into chromatography columns and resins, filters, membrane absorbers, and other products. By system, it is bifurcated into single use system and re-usable system. By application, it is divided into monoclonal antibody production, vaccine production, insulin production, immunoglobulin production, erythropoietin production, and other applications. By end user, it is categorized into biopharmaceutical manufacturers, and contract manufacturing organizations (CMOs). Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA). North America accounted for the largest market share in the downstream processing market in 2020 and is expected to retain its dominance throughout the forecast period. This is primarily attributed to increase in R&D activities for biopharmaceuticals, considerable investments made by the market players and increase in government support are fueling the growth of the market in this region. The major companies profiled in this report include, 3M Company, Sartorius Stedim Biotech S.A, Danaher Corporation, Thermo Fisher Scientific Inc., Merck & Co., Inc., Boehringer Ingelheim, Lonza Group AG, Eppendorf AG, Finesse Solutions, Inc. and Repligen Corporation Key Benefits For Stakeholders This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of theDownstream Processing Market Size analysis from 2020 to 2030 to identify the prevailing downstream processing market opportunities. The market research is offered along with information related to key drivers, restraints, and opportunities. Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network. In-depth analysis of the downstream processing market segmentation assists to determine the prevailing market opportunities. Major countries in each region are mapped according to their revenue contribution to the global market. Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players. The report includes the analysis of the regional as well as global downstream processing market trends, key players, market segments, application areas, and market growth strategies. Key Topics Covered: CHAPTER 4: DOWNSTREAM PROCESSING MARKET, BY TECHNOLOGY 4.1 Overview 4.2 Purification 4.2.2 Market size and forecast, by region 4.2.3 Market analysis by country 4.3 Separation 4.3.2 Market size and forecast, by region 4.3.3 Market analysis by country 4.4 Clarification/Concentration 4.4.2 Market size and forecast, by region 4.4.3 Market analysis by country CHAPTER 5: DOWNSTREAM PROCESSING MARKET, BY PRODUCT 5.1 Overview 5.2 Chromatography Columns and Resins 5.2.1 Key market trends, growth factors and opportunities 5.2.2 Market size and forecast, by region 5.2.3 Market analysis by country 5.3 Filters 5.3.2 Market size and forecast, by region 5.3.3 Market analysis by country 5.4 Membrane Adsorbers 5.4.2 Market size and forecast, by region 5.4.3 Market analysis by country 5.5 Other Products 5.5.2 Market size and forecast, by region 5.5.3 Market analysis by country CHAPTER 6: DOWNSTREAM PROCESSING MARKET, BY SYSTEM 6.1 Overview 6.2 Single Use System 6.2.2 Market size and forecast, by region 6.2.3 Market analysis by country 6.3 Re Usable System 6.3.2 Market size and forecast, by region 6.3.3 Market analysis by country CHAPTER 7: DOWNSTREAM PROCESSING MARKET, BY APPLICATION 7.1 Overview 7.2 Monoclonal Antibody Production 7.2.2 Market size and forecast, by region 7.2.3 Market analysis by country 7.3 Vaccine Production 7.3.2 Market size and forecast, by region 7.3.3 Market analysis by country 7.4 Insulin Production 7.4.2 Market size and forecast, by region 7.4.3 Market analysis by country 7.5 Immunoglobulin Production 7.5.2 Market size and forecast, by region 7.5.3 Market analysis by country 7.6 Erythropoietin Production 7.6.2 Market size and forecast, by region 7.6.3 Market analysis by country 7.7 Other Applications 7.7.2 Market size and forecast, by region 7.7.3 Market analysis by country CHAPTER 8: DOWNSTREAM PROCESSING MARKET, BY END USER 8.1 Overview 8.2 Biopharmaceutical Manufacturers 8.2.2 Market size and forecast, by region 8.2.3 Market analysis by country 8.3 Contract Manufacturing Organizations (CMOs) 8.3.1 Key market trends, growth factors and opportunities 8.3.2 Market size and forecast, by region 8.3.3 Market analysis by country CHAPTER 9: DOWNSTREAM PROCESSING MARKET, BY REGION CHAPTER 10: COMPANY LANDSCAPE

Merck & Co. Investments

24 Investments

Merck & Co. has made 24 investments. Their latest investment was in Aktis Oncology as part of their Series A - II on August 8, 2022.

CBI Logo

Merck & Co. Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

8/25/2022

Series A - II

Aktis Oncology

$84M

Yes

4

8/16/2022

Series B

Orna Therapeutics

$221M

Yes

3

8/10/2022

Corporate Minority

Cerevance

$25M

Yes

4

4/29/2022

Series C - II

Subscribe to see more

Subscribe to see more

10

9/14/2020

Corporate Minority - P2P

Subscribe to see more

$99M

Subscribe to see more

10

Date

8/25/2022

8/16/2022

8/10/2022

4/29/2022

9/14/2020

Round

Series A - II

Series B

Corporate Minority

Series C - II

Corporate Minority - P2P

Company

Aktis Oncology

Orna Therapeutics

Cerevance

Subscribe to see more

Subscribe to see more

Amount

$84M

$221M

$25M

$99M

New?

Yes

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

4

3

4

10

10

Merck & Co. Portfolio Exits

26 Portfolio Exits

Merck & Co. has 26 portfolio exits. Their latest portfolio exit was SAB Biotherapeutics on October 25, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

10/25/2021

Reverse Merger

$99M

3

8/18/2021

Acquired

$99M

32

6/3/2021

Spinoff / Spinout

Organon & Co

$99M

2

3/22/2021

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

8/24/2020

Reverse Merger

Subscribe to see more

$99M

Subscribe to see more

10

Date

10/25/2021

8/18/2021

6/3/2021

3/22/2021

8/24/2020

Exit

Reverse Merger

Acquired

Spinoff / Spinout

Acquired

Reverse Merger

Companies

Organon & Co

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Sources

3

32

2

10

10

Merck & Co. Acquisitions

34 Acquisitions

Merck & Co. acquired 34 companies. Their latest acquisition was Mecaro - Chemical Business on August 17, 2022.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

8/17/2022

$99M

Acquired Unit

3

9/30/2021

Series E+

$99M

$136.52M

Acq - Pending

6

4/1/2021

Series B

$99M

$138M

Acq - P2P

18

11/23/2020

Series B

Subscribe to see more

$99M

$99M

Subscribe to see more

10

11/5/2020

Series B

Subscribe to see more

$99M

$99M

Subscribe to see more

10

Date

8/17/2022

9/30/2021

4/1/2021

11/23/2020

11/5/2020

Investment Stage

Series E+

Series B

Series B

Series B

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Total Funding

$136.52M

$138M

$99M

$99M

Note

Acquired Unit

Acq - Pending

Acq - P2P

Subscribe to see more

Subscribe to see more

Sources

3

6

18

10

10

Merck & Co. Partners & Customers

10 Partners and customers

Merck & Co. has 10 strategic partners and customers. Merck & Co. recently partnered with NMS Group on September 9, 2022.

Date

Type

Business Partner

Country

News Snippet

Sources

9/21/2022

Licensor

Italy

Merck Enters Collaboration and Option to License Agreement with Nerviano Medical Sciences to Develop Next-Generation PARP1 Selective Inhibitor

During the option period , Nerviano Medical Sciences S.r.l. and Merck will collaborate on the clinical development of Nerviano Medical Sciences S.r.l.-293 , with Nerviano Medical Sciences S.r.l. designing , sponsoring , conducting , and funding global clinical trials .

1

9/14/2022

Partner

South Korea

Qurient Announces Collaboration Agreement with MSD to Evaluate Selective CDK7 Inhibitor Q901 in Combination With KEYTRUDA® (pembrolizumab)

SEONGNAM-SI , South Korea -- -- Qurient , a clinical-stage biotech company based in Korea , today announced that the company has entered into a clinical collaboration agreement with MSD , for clinical study of Q901 , a selective CDK7 inhibitor in combination with MSD 's anti-PD-1 therapy KEYTRUDA .

1

8/16/2022

Licensor

United States

Merck and Orna Therapeutics Collaborate to Advance Orna’s Next Generation of RNA Technology

RAHWAY , N.J. & CAMBRIDGE , Mass. -- -- Merck & Co. , Inc. , known as MSD outside the United States and Canada , and Orna Therapeutics , a biotechnology company pioneering a new investigational class of engineered circular RNA therapies , today announced a collaboration agreement to discover , develop , and commercialize multiple programs , including vaccines and therapeutics in the areas of infectious disease and oncology .

2

8/10/2022

Vendor

United States

Subscribe to see more

Subscribe to see more

10

7/21/2022

Partner

United States

Subscribe to see more

Subscribe to see more

10

Date

9/21/2022

9/14/2022

8/16/2022

8/10/2022

7/21/2022

Type

Licensor

Partner

Licensor

Vendor

Partner

Business Partner

Country

Italy

South Korea

United States

United States

United States

News Snippet

Merck Enters Collaboration and Option to License Agreement with Nerviano Medical Sciences to Develop Next-Generation PARP1 Selective Inhibitor

During the option period , Nerviano Medical Sciences S.r.l. and Merck will collaborate on the clinical development of Nerviano Medical Sciences S.r.l.-293 , with Nerviano Medical Sciences S.r.l. designing , sponsoring , conducting , and funding global clinical trials .

Qurient Announces Collaboration Agreement with MSD to Evaluate Selective CDK7 Inhibitor Q901 in Combination With KEYTRUDA® (pembrolizumab)

SEONGNAM-SI , South Korea -- -- Qurient , a clinical-stage biotech company based in Korea , today announced that the company has entered into a clinical collaboration agreement with MSD , for clinical study of Q901 , a selective CDK7 inhibitor in combination with MSD 's anti-PD-1 therapy KEYTRUDA .

Merck and Orna Therapeutics Collaborate to Advance Orna’s Next Generation of RNA Technology

RAHWAY , N.J. & CAMBRIDGE , Mass. -- -- Merck & Co. , Inc. , known as MSD outside the United States and Canada , and Orna Therapeutics , a biotechnology company pioneering a new investigational class of engineered circular RNA therapies , today announced a collaboration agreement to discover , develop , and commercialize multiple programs , including vaccines and therapeutics in the areas of infectious disease and oncology .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

1

2

10

10

Merck & Co. Service Providers

2 Service Providers

Merck & Co. has 2 service provider relationships

Service Provider

Associated Rounds

Provider Type

Service Type

Acq - P2P

Counsel

General Counsel

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Service Provider

Subscribe to see more

Associated Rounds

Acq - P2P

Subscribe to see more

Provider Type

Counsel

Subscribe to see more

Service Type

General Counsel

Subscribe to see more

Partnership data by VentureSource

Merck & Co. Team

113 Team Members

Merck & Co. has 113 team members, including current Chief Executive Officer, President, Robert M. Davis.

Name

Work History

Title

Status

Robert M. Davis

Chief Executive Officer, President

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Name

Robert M. Davis

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Work History

Title

Chief Executive Officer, President

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

You May Also Like

Cargill Logo
Cargill

Cargill provides food, agriculture, financial, and industrial products and services to the world. Working together with farmers, customers, governments, and communities, Cargill remains committed to feeding the world in a responsible way that reduces environmental impact.

Invetx Logo
Invetx

Invetx is developing mAbs for chronic and serious conditions in dogs and cats with the goal to extend and improve their quality of life. It was founded in 2018 and is based in Boston, Massachusetts.

B
Bugworks Research

Bugworks Research is a drug discovery company that aims to discover novel biopharmaceutical assets for the treatment of antibiotic resistant bacterial infections. Bugworks combines functional proteomics with sophisticated semiconductor design principles to model and manipulate various bacterial systems. Its model of E. coli is modular and adaptable to tackle a broad spectrum of pathogens that afflict large communities, hospitals and ICUs alike. The Bugworks Microbial Platform (BMP) is also capable of modeling the behavior and effect of biofilm formation. This permits the evaluation of both phenotypic and genotypic resistance mechanisms, allowing for the design of targeted therapies.

A
Animal Industry Data Korea

Animal Industry Data Korea is the developer of farmsplan, a healthcare solution for livestock based on animal genetics research and biometric data analysis. With farmsplan, farmers can collect data and manage farm records, monitor the health status of their pigs, test a pig's blood and form their health plan, manage breeding schedules, and improve productivity. The company serves farmers. Animal Industry Data Korea was founded in 2017 and is based in Seoul, South Korea.

D
DoubleRainbow Biosciences

DoubleRainbow Biosciences develops technologies rooted in the mechanistic understanding of specialized metabolic systems in plants and other organisms. The firm devises biosynthetic strategies that provide sustainable access to high-value natural products of medicinal or industrial significance.

Spero Therapeutics Logo
Spero Therapeutics

Spero Therapeutics (NASDAQ: SPRO) is a global multi-asset clinical-stage biopharmaceutical company that develops a pipeline of antibacterials focused on the unmet needs of patients with drug-resistant bacterial infections. It serves clients in the healthcare sector. The company was founded in 2013 and is based in Cambridge, Massachusetts.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.